An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

Subject dosing is complete in a phase 1/2 clinical trial of an allogeneic cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction, according to a press release.

References: Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015;2:17.

Each patient received 5 injections of ranibizumab given at baseline, then at 1, 2, 4, and 6 months. Patients were followed for a total of 12 months.

The CLARA Phase 1/2 clinical trial (NCT06041256) is a prospective, multi-center, randomized, double-masked, parallel-arm dose-ranging clinical trial designed to assess the safety, tolerability ...

Eclipse Life Sciences has enrolled and dosed the first patient in the BETTIS-1 phase 2 clinical trial investigating the EC-104 implant for the treatment of diabetic macular edema, according to a ...

Treatments for acromegaly, edema, HSCT-associated thrombotic microangiopathy, multiple sclerosis, and spinal muscular atrophy are under review.

The global Diabetic Macular Edema Market Size is expected to reach a valuation of US$ 3.7 Billion by the end of 2022, and further expand at a CAGR of 1.2% from 2022 to 2032. The market is projected to ...

ION is the most common acute optic neuropathy in older patients, with an annual incidence estimated at 2.3 to 10.2 cases per 100,000 persons 50 years of age or older. 1–5 ...

During the next 2 days they carried packs weighing 40 to 50 pounds over a 12,000-foot pass in deep snow and cold weather. On December 30 R.C., the patient, noted dyspnea, weakness and cough.

SEATTLE & CAMBRIDGE, Mass. & TOKYO — Aurion Biotech, Inc. (Aurion Biotech), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced ...